At a glance
ClinicalIndex Comparison RecordN/ACompleted· 93 enrolled
Drug / intervention
Etanercept (Enbrel)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Observational Study to Monitor Safety in Patients Who Were Administered With Etanercept (Enbrel) 25 mg by Subcutaneous Injection
Wyeth is now a wholly owned subsidiary of Pfizer·observational·Posted May 23, 2008·Updated Nov 16, 2010
In Brief
An observational study evaluating Etanercept (Enbrel) for Arthritis, Psoriatic. Completed, enrolled 93 participants across 1 site.
Detailed Summary
The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Psoriatic
CountriesPhilippines
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedMay 2008
Primary CompletionOct 2009
TodayJul 2026
First PostedMay 23, 2008
Enrollment StartJan 1, 2007
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.1 years ago
Interventions
Etanercept (Enbrel)drug